- Home
- RELY vs VRDN Comparison
RELY vs VRDN Comparison
Compare RELY & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RELY | VRDN |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RELY | VRDN |
|---|---|---|
| Price | $15.56 | $27.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $24.13 | ★ $40.92 |
| AVG Volume (30 Days) | ★ 4.4M | 1.0M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.16 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,635,147,000.00 | $5,706,000.00 |
| Revenue This Year | $21.82 | $27.65 |
| Revenue Next Year | $19.08 | $253.29 |
| P/E Ratio | $50.34 | ★ N/A |
| Revenue Growth | ★ 29.37 | N/A |
| 52 Week Low | $12.08 | $9.90 |
| 52 Week High | $24.63 | $34.29 |
Technical Indicators
Market Signals| Indicator | RELY | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 48.00 | 39.60 |
| Support Level | $14.72 | $26.31 |
| Resistance Level | $15.77 | $33.71 |
| Average True Range (ATR) | 0.65 | 1.27 |
| MACD | -0.27 | -0.07 |
| Stochastic Oscillator | 14.45 | 12.93 |
Price Performance
Historical ComparisonAbout RELY Remitly Global Inc.
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).